← Back to search
TUFTS MEDICAL CENTER PARENT, INC.
BOSTON, MA, 02111
UnclaimedClaim this profile (free)
Subcontracting experience
3 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | TUFTS UNIVERSITY WILL BE RESPONSIBLE FOR IDENTIFYING PATIENTS WITH LYME DISEASE IN THE TUFTSMEDICINE HOSPITAL AND
PRIMARY CARE NETWORK THROUGH REGULARLY SCHEDULED ELECTRONIC HEALTH RECORDS (EHR) SCANS AND EXTRACTING CLINICAL
INFORMATION TO PROVIDE DEIDENTIFIED DETAILS OF THE DISEASE TO A COMBINED DATABASE AT MASSACHUSETTS GENERAL
HOSPITAL (MGH) FOR SUBSEQUENT TRANSMISSION TO THE CDC. TUFTS UNIVERSITY INVESTIGATORS WILL WORK WITH MGH
INVESTIGATORS TO CREATE A UNIFIED AND EFFECTIVE CASE DEFINITION FOR IDENTIFYING PATIENTS WITH LYME DISEASE.TUFTS
UNIVERSITY INVESTIGATORS WILL ASSIST IN THE MODEL DEVELOPMENT, VALIDATION, AND DEPLOYMENT PROCESS AS DESCRIBED
IN THE FULL PROPOSAL. WE WILL FIRST DEVELOP A BASELINE MODEL OF SUBJECTS PRESENTING TO TUFTSMEDICINE WHO ARE
DIAGNOSED AS HAVING LYME DISEASE BY ICD9/10 CODES. WE WILL THEN WORK WITH MASS GENERAL BRIGHAM AND
MAINEHEALTH TO DERIVE ONE OR MORE IMPROVED MODELS BY IDENTIFYING INFORMATIVE DIAGNOSTIC CRITERIA FROM CLINICAL,
MICROBIOLOGICAL, EPIDEMIOLOGY, AND FREE TEXT DATA IN CASE AND CONTROL VISITS. WE WILL COMPARE THE PERFORMANCE OF
ONE OR MORE IMPROVED MODELS AND SELECT THE BEST-PERFORMING ONE. WE WILL IMPLEMENT THE BEST-PERFORMING
MODEL FOR RECORDS AT TUFTS UNIVERSITY, SUMMARIZE THE RESULTS, AND AGGREGATE SUMMARY STATISTICS ACROSS SITES.
BASED ON A UNIFIED, EFFECTIVE CASE DEFINITION AND A ROBUST MODEL TO IDENTIFY CASES OF LYME DISEASE FROM EHR
DATA, WE WILL CONDUCT TARGETED COLLECTIONS. WE WILL IDENTIFY POTENTIAL RECRUITMENT OPPORTUNITIES FOR RESEARCH
SUBJECTS BASED ON SPECIFIC CRITERIA (E.G. NEUROBORRELIOSIS, PREGNANCY, SUSPECTED CO-INFECTIONS, VACCINATION
RECIPIENT) DEFINED IN CONSULTATION WITH THE FULL INVESTIGATOR TEAM AND THE RELEVANT TECHNICAL TEAM AT CDC. WE WILL
ENROLL A SUBSET OF THESE INDIVIDUALS IN CLINICAL STUDIES TO ASSESS ASPECTS OF LYME DISEASE POTENTIALLY INCLUDING THE
PERFORMANCE OF DIAGNOSTIC ASSAYS, THE OUTCOMES OF PREGNANCY-ASSOCIATED LYME DISEASE, AND VACCINE EFFICACY. 244266 Parent award context Parent award agency: Department of Health and Human Services · Centers for Disease Control and Prevention Parent award NAICS: 541720 Parent award performance state: MA Parent award description: HARNESSING ELECTRONIC HEALTH RECORDS FOR SURVEILLANCE OF LYME DISEASE View parent award on USAspending | — | $354,971 | Apr 18, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | DR. MAJD ALSOUBANI OF TUFTS MEDICAL CENTER, INC. WILL BE SUPPORTING A SYSTEMATIC REVIEW PROJECT SPONSORED BY CARB-X TO HELP DEFINE AN EVIDENCE-BASED CLINICAL DEVELOPMENT FRAMEWORK FOR THE EVALUATION OF DECOLONIZATION AGENTS USED FOR THE PREVENTION OF SERIOUS BACTERIAL INFECTIONS. MICROBIAL COLONIZATION OF MUCOSAL SURFACES AND SKIN BY ANTIBIOTIC RESISTANT MICROBES IS AN IMPORTANT DRIVER OF INTRACTABLE INFECTIONS IN COLONIZED INDIVIDUALS. DECOLONIZATION OF SKIN AND MUCOSA HAS BEEN SHOWN TO REDUCE RATES OF PATIENT INFECTION IN SEVERAL HEALTHCARE SETTINGS. IMPORTANTLY, AN ADDITIONAL PUBLIC HEALTH BENEFIT IS THAT DECOLONIZATION MAY DECREASE PERSON-TO-PERSON OR ENVIRONMENTAL TRANSMISSION IN HEALTH CARE FACILITIES. THEREFORE, DECOLONIZATION AGENTS MAY PRODUCE TWO DIFFERENT, BUT RELATED, BENEFICIAL CLINICAL OUTCOMES. INNOVATORS AND PRODUCT DEVELOPERS ARE EXPLORING €œNON-TRADITIONAL€Ͽ½ NOVEL ANTI-INFECTIVES THAT ARE MICROBIOME-SPARING BY SELECTIVELY TARGETING PATHOGENS SUCH AS LIVE BIOTHERAPEUTIC PRODUCTS (LBPS), WHICH SEEK TO DISPLACE POTENTIALLY HARMFUL BACTERIA IN CERTAIN TARGET BODY SITES, AND ENGINEERED BACTERIOPHAGE PRODUCTS, WHICH SEEK TO EXCISE HARMFUL BACTERIA FROM CERTAIN TARGET BODY SITES. THE DEVELOPMENT OF NOVEL, NON-TRADITIONAL DECOLONIZATION AGENTS TO PREVENT BREAKTHROUGH INFECTIONS IN PATIENTS COLONIZED WITH ANTIBIOTIC-RESISTANT BACTERIA, OR TO DECREASE PERSON-TO-PERSON TRANSMISSION IN HEALTHCARE SETTINGS, IS HINDERED BY THE LACK OF DEFINED REGULATORY AND CLINICAL DEVELOPMENT PATHWAYS FOR APPROVAL. THIS SYSTEMATIC REVIEW IS INTENDED TO UNDERSCORE WHAT IS CURRENTLY KNOWN ABOUT THE RELATIONSHIP BETWEEN COLONIZATION AND INFECTION RISK AND/OR TRANSMISSION OF ANTIBIOTIC-RESISTANT PATHOGENS. THE REVIEW WILL BE FOLLOWED BY A GAP ANALYSIS TO IDENTIFY AREAS WHERE NEW OBSERVATIONAL STUDIES ARE REQUIRED TO PROVIDE THE EVIDENCE-BASE TO SUPPORT THE DESIGN OF STUDIES TO SUPPORT THE APPROVAL OF NOVEL DECOLONIZATION AGENTS. 4500004937 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $101,301 | Feb 21, 2024 | — – — |
| Subcontractor | Department of Defense | R&D-SCHOOLS, NON-MIT 7000585543 Parent award context Parent award agency: Department of Defense · Department of the Air Force Parent award NAICS: 541712 Parent award performance state: MA Parent award description: IGF::CT::IGF TASK ORDER 0001 FOR DOD LINE FUNDING View parent award on USAspending | FA870215D0001USAspending | $164,465 | Aug 21, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.